# Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

> **NCT00434304** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 62 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ropinirole prolonged release/extended release(PR/XR)

## Key facts

- **NCT ID:** NCT00434304
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-09
- **Primary completion:** 2009-03-01
- **Final completion:** 2009-03-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434304, "Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00434304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*